{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:01:10Z","timestamp":1783620070868,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40263-013-0104-8","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T08:23:58Z","timestamp":1376900638000},"page":"1081-1092","source":"Crossref","is-referenced-by-count":78,"title":["Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit\/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study"],"prefix":"10.1007","volume":"27","author":[{"given":"Ralf W.","family":"Dittmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Cardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hodgkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Civil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"issue":"6","key":"104_CR1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942\u20138.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"104_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/11599630-000000000-00000","volume":"26","author":"P Hodgkins","year":"2012","unstructured":"Hodgkins P, Shaw M, McCarthy S, Sallee FR. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? CNS Drugs. 2012;26(3):245\u201368.","journal-title":"CNS Drugs."},{"key":"104_CR3","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Process of care supplemental appendix. Pediatrics. 2011a;128:SI1-21. http:\/\/pediatrics.aappublications.org\/content\/suppl\/2011\/10\/11\/peds.2011-2654.DC1\/zpe611117822p.pdf . Accessed 04 April 2013.","DOI":"10.1542\/peds.digest1284"},{"key":"104_CR4","unstructured":"National Institute for Health and Clinical Excellence. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. London, UK; 2009. http:\/\/wwwniceorguk\/nicemedia\/live\/12061\/42060\/42060pdf . Accessed 04 April 2013."},{"key":"104_CR5","first-page":"215","volume":"5","author":"P Hammerness","year":"2009","unstructured":"Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009;5:215\u201326.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"15","key":"104_CR6","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1517\/14656566.2010.517523","volume":"11","author":"FR Sallee","year":"2010","unstructured":"Sallee FR, Eaton K. Guanfacine extended-release for attention-deficit\/hyperactivity disorder (ADHD). Expert Opin Pharmacother. 2010;11(15):2549\u201356. doi: 10.1517\/14656566.2010.517523 .","journal-title":"Expert Opin Pharmacother."},{"issue":"5","key":"104_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/11208100-000000000-00000","volume":"13","author":"JD Croxtall","year":"2011","unstructured":"Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011;13(5):329\u201336.","journal-title":"Paediatr Drugs."},{"key":"104_CR8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"9","key":"104_CR9","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364\u201373.","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"104_CR10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2007.04.015","volume":"62","author":"J Biederman","year":"2007","unstructured":"Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970\u20136.","journal-title":"Biol Psychiatry."},{"issue":"3","key":"104_CR11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450\u201363.","journal-title":"Clin Ther."},{"key":"104_CR12","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;. doi: 10.1016\/j.euroneuro.2012.11.012 .","journal-title":"Eur Neuropsychopharmacol."},{"issue":"4","key":"104_CR13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"1","key":"104_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"104_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-9081-6-34","volume":"6","author":"T Wigal","year":"2010","unstructured":"Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.","journal-title":"Behav Brain Funct."},{"key":"104_CR16","volume-title":"Guideline for good clinical practice E6(R1)","author":"ICH harmonised tripartite guideline","year":"1996","unstructured":"ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996."},{"key":"104_CR17","unstructured":"American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and statistical manual of mental disorders, 4th ed. Text revision. DSM-IV-TR\u2122 Washington, DC: American Psychiatric Association; 2000. p. 85\u201393."},{"key":"104_CR18","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH, Psychopharmacology Research Branch Division of Extramural Research Programs; 1976. p. 218\u201322."},{"key":"104_CR19","volume-title":"The ADHD Rating Scale-IV, checklist, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power T, Anastopoulos A, Reid R. The ADHD Rating Scale-IV, checklist, norms, and clinical interpretation. New York: Guildford Press; 1998."},{"issue":"2","key":"104_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF03256752","volume":"23","author":"P Mozzicato","year":"2009","unstructured":"Mozzicato P. MedDRA: an overview of the medical dictionary for regulatory activities. Pharm Med. 2009;23(2):11.","journal-title":"Pharm Med."},{"key":"104_CR21","unstructured":"Centers for Disease Control and Prevention. http:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm . Accessed 04 April 2013."},{"issue":"1","key":"104_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/104454601750143500","volume":"11","author":"CW Hughes","year":"2001","unstructured":"Hughes CW, Rintelmann J, Emslie GJ, Lopez M, MacCabe N. A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adolesc Psychopharmacol. 2001;11(1):77\u201393.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"104_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1\u2013100.","journal-title":"Acta Psychiatr Scand Suppl."},{"issue":"7","key":"104_CR24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/appi.ajp.164.7.1035","volume":"164","author":"K Posner","year":"2007","unstructured":"Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035\u201343.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"104_CR25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2307\/2533017","volume":"51","author":"KK Lan","year":"1995","unstructured":"Lan KK, Rosenberger WF, Lachin JM. Sequential monitoring of survival data with the Wilcoxon statistic. Biometrics. 1995;51(3):1175\u201383.","journal-title":"Biometrics."},{"issue":"1","key":"104_CR26","first-page":"12","volume":"65","author":"RL Prentice","year":"1978","unstructured":"Prentice RL. Linear rank tests with right censored data. Biometrika. 1978;65(1):12.","journal-title":"Biometrika."},{"issue":"1","key":"104_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112(1):155\u20139.","journal-title":"Psychol Bull."},{"issue":"2","key":"104_CR28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","volume":"53","author":"D Michelson","year":"2003","unstructured":"Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112\u201320.","journal-title":"Biol Psychiatry."},{"issue":"11","key":"104_CR29","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","volume":"159","author":"D Michelson","year":"2002","unstructured":"Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896\u2013901.","journal-title":"Am J Psychiatry."},{"issue":"5","key":"104_CR30","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1542\/peds.108.5.e83","volume":"108","author":"D Michelson","year":"2001","unstructured":"Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR et al. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.","journal-title":"Pediatrics."},{"issue":"1","key":"104_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1753-2000-5-35","volume":"5","author":"R Jain","year":"2011","unstructured":"Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, et al. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit\/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health. 2011;5(1):35.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"issue":"9","key":"104_CR32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00787-012-0286-5","volume":"21","author":"P Hodgkins","year":"2012","unstructured":"Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit\/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477\u201392.","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"104_CR33","author":"PM Wehmeier","year":"2012","unstructured":"Wehmeier PM, Dittmann RW, Banaschewski T, Schacht A. Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology? J Atten Disord. 2012. doi: 108705471244518410.1177\/1087054712445184 .","journal-title":"J Atten Disord."},{"issue":"5","key":"104_CR34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","volume":"48","author":"JH Newcorn","year":"2009","unstructured":"Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):511\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"6","key":"104_CR35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","volume":"165","author":"JH Newcorn","year":"2008","unstructured":"Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721\u201330.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"104_CR36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2006.01.052","volume":"149","author":"TE Wilens","year":"2006","unstructured":"Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with attention-deficit\/hyperactivity disorder. J Pediatr. 2006;149(1):112\u20139.","journal-title":"J Pediatr."},{"issue":"12","key":"104_CR37","first-page":"678","volume":"34","author":"SV Faraone","year":"2009","unstructured":"Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit\/hyperactivity disorder in youths. P T. 2009;34(12):678\u201394.","journal-title":"P T."},{"key":"104_CR38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-244X-11-176","volume":"11","author":"R Hanwella","year":"2011","unstructured":"Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.","journal-title":"BMC Psychiatry."},{"issue":"8","key":"104_CR39","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/adc.2004.056952","volume":"90","author":"A Poulton","year":"2005","unstructured":"Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90(8):801\u20136.","journal-title":"Arch Dis Child."},{"key":"104_CR40","doi-asserted-by":"crossref","unstructured":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894\u2013921.","DOI":"10.1097\/chi.0b013e318054e724"},{"issue":"3","key":"104_CR41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227\u201346.","journal-title":"J Child Psychol Psychiatry."},{"issue":"3","key":"104_CR42","first-page":"9","volume":"17","author":"DW Goodman","year":"2010","unstructured":"Goodman DW, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry. 2010;17(3):9.","journal-title":"Primary Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0104-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0104-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:22Z","timestamp":1551186742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0104-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0104-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}